John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TAST
2276
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $238K | ﹤0.01% |
105,338
+24,088
| +30% | +$61.9K |
|
2277
4D Molecular Therapeutics
FDMT
$868M
| $237K | ﹤0.01% |
15,700
-55,147
| -78% | -$866K |
|
2278
National Healthcare
NHC
$3.52B
| $237K | ﹤0.01% |
3,378
-378
| -10% | -$25.4K |
|
2279
Stoke Therapeutics
STOK
$2.16B
| $237K | ﹤0.01% |
11,242
-11,285
| -50% | -$226K |
|
2280
Tootsie Roll Industries
TR
$3.11B
| $237K | ﹤0.01% |
7,637
+169
| +2% | +$5.04K |
|
2281
EyePoint Inc
EYPT
$431M
| $236K | ﹤0.01% |
19,456
-173,559
| -90% | -$1.9M |
|
2282
Erasca
ERAS
$6.21B
| $235K | ﹤0.01% |
+27,379
| New | +$317K |
|
2283
Mistras Group
MG
$605M
| $235K | ﹤0.01% |
35,623
+22,291
| +167% | +$152K |
|
2284
Ginkgo Bioworks
DNA
$508M
| $234K | ﹤0.01% |
+1,452
| New | +$283K |
|
2285
Korro Bio
KRRO
$202M
| $234K | ﹤0.01% |
2,208
+113
| +5% | +$21.6K |
|
2286
Braskem
BAK
$650M
| $231K | ﹤0.01% |
+12,400
| New | +$235K |
|
2287
MGP Ingredients
MGPI
$384M
| $231K | ﹤0.01% |
2,700
-4,849
| -64% | -$391K |
|
|
AXU
2288
DELISTED
Alexco Resource Corp
AXU
| $228K | ﹤0.01% |
147,041
+64,811
| +79% | +$108K |
|
|
MYOV
2289
DELISTED
Myovant Sciences Ltd.
MYOV
| $227K | ﹤0.01% |
+17,022
| New | +$228K |
|
|
AHG
2290
Akso Health Group
AHG
$843M
| $226K | ﹤0.01% |
133,852
-60,030
| -31% | -$95.4K |
|
2291
Caribou Biosciences
CRBU
$189M
| $225K | ﹤0.01% |
+24,456
| New | +$258K |
|
|
EIGR
2292
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $225K | ﹤0.01% |
+903
| New | +$143K |
|
2293
Canadian Solar
CSIQ
$970M
| $223K | ﹤0.01% |
6,314
-4,541
| -42% | -$137K |
|
2294
Solid Biosciences
SLDB
$1.06B
| $222K | ﹤0.01% |
12,320
-15,030
| -55% | -$265K |
|
|
SYRS
2295
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $222K | ﹤0.01% |
18,637
+13,770
| +283% | +$246K |
|
|
REGI
2296
DELISTED
Renewable Energy Group, Inc.
REGI
| $222K | ﹤0.01% |
3,654
-3,966
| -52% | -$192K |
|
2297
KVH Industries
KVHI
$137M
| $221K | ﹤0.01% |
+24,277
| New | +$217K |
|
|
GMBL
2298
DELISTED
Esports Entertainment Group Inc. Common Stock
GMBL
| $221K | ﹤0.01% |
+8
| New | +$686K |
|
|
ZYNE
2299
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $221K | ﹤0.01% |
107,747
+81,651
| +313% | +$194K |
|
|
CPE
2300
DELISTED
Callon Petroleum Company
CPE
| $220K | ﹤0.01% |
3,721
-434,223
| -99% | -$23.8M |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.